Secondary amines as renin inhibitors

Details Secondary amines as renin inhibitors Secondary amines as renin inhibitors

2011-06-28

2011-06-28

Andres, Janet L (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C564S305000

Reexamination Certificate

active

07968720

ABSTRACT:
The invention relates to novel secondary amine derivatives of formula (I) and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin.

REFERENCES:
patent: 5380758 (1995-01-01), Stamler
patent: 5703073 (1997-12-01), Garvey
patent: 5994294 (1999-11-01), Garvey
patent: 6218417 (2001-04-01), del Soldato
patent: 6242432 (2001-06-01), del Soldato
patent: 7427613 (2008-09-01), Bezencon et al.
patent: 2008/0161313 (2008-07-01), Bezencon et al.
patent: 2008/0214598 (2008-09-01), Bezencon et al.
patent: 2009/0062342 (2009-03-01), Bezencon et al.
patent: 2009/0176823 (2009-07-01), Bezencon et al.
patent: 2009/0306123 (2009-12-01), Bezencon et al.
patent: WO97/09311 (1997-03-01), None
patent: WO98/19672 (1998-05-01), None
patent: WO03/093267 (2003-11-01), None
patent: WO2004/002957 (2004-01-01), None
patent: WO2004/096366 (2004-11-01), None
patent: WO2004/096769 (2004-11-01), None
patent: WO2004/096799 (2004-11-01), None
patent: WO2004/096803 (2004-11-01), None
patent: WO2006/069788 (2006-07-01), None
patent: WO2006/129237 (2006-12-01), None
Patani et. al., “Bioisosterism: A Rational Approach in Drug Design”, Chem. Rev. 1996, 96, pp. 3147-3176.
U.S. Appl. No. 11/915,594, Bezencon, et al.
Azizi et al., Blood pressure effects of acute intravenous rennin or oral angiotensin converting enzyme inhibition in essential hypertension, J. Hypertens, 1994, 12, 419.
Blough et al., Synthesis and transporter binding properties of 3β-[4′-Phenylalkyl,-phenylakenyl, and -phenylalkynl)phenyl] topane-2β-carboxylic acid methyl ester: evidence of a remote phenyl binding domain on the dopamine transporter, Med.Chem., 2002, 45, 4029.
Breyer et al., Angiotensin converting enzyme inhibition in diabetic nephropathy, Kidney International, 1994, 45, S156.
Carroll et al., Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl) tropane-2-carboxylic acid methyl ester isomers, J.Med.Chem., 2004, 47, 6401.
Cossy et al., A formal synthesis of (−)-paroxetine by enantioselective ring enlargement of a trisubstituted prolinol, European J. Org. Chem., 2002, 21, 3543.
Fischli et al., Ro 42-5892 is a potent orally active renin inhibitor in primates, Hypertension, 1991, 18:22-31.
Fouad-Tarazi et al., The renin-angiotensin system and treatment of heart failure, Am. J. Med., 1988, 84 (Suppl.3A), 83.
Gibson, Editor, Pharmaceutical Preformulation and Formulation, IHS Health Group, Englewood CO, USA 2001.
Gould, Salt selection for basic drugs, Int. J. Pharm. 1986, 33, 201-217.
Husain, The chymase-angiotensin system in humans, J. Hypertens., 1993, 11, 1155.
Israili et al., Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy, Annals of Internal Medicine, 1992, 117, 234.
Jurkauskas et al., Conjugate reduction of α,β-unsaturated carbonyl compounds catalyzed by a copper carbene complex, Org.Letters, 2003, 5, 2417.
Kleinert, Renin inhibition, Cardiovasc. Drugs, 1995, 9, 645.
Marki et al., Piperidine renin inhibitors: from leads to drug candidates, IL Farmaco, 2001, 56, 21.
Mealy et al., Aliskiren fumarate, Drugs of the Future, 2001, 26, 1139.
Meltzer et al., Synthesis and biological activity of 2-carbomethoxy-3-catechol-8-azabicyclo[3.2.1]octanes, Bioorg. Med. Chem. Letters, 2003, 13, 4133.
Murthy et al., Enantioselective synthesis of 3-substituted-4-aryl piperdines useful for the preparation of paroxetine, Science Direct, Tetrahedron Letters, 2003, 44, 5355.
Neutel et al., Immediate blood pressure effects of the renin inhibitor enalkiren and the angiotensis-converting enzyme inhibitor enalaprilat, Am. Heart, 1991, 122, 1094.
Oae et al., Organic thionitrites and related substances, a review, Org. Prep. Proc. Int. 15(3): 165-198, 1983.
Oefner et al., Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartic proteinases?, Chem. Biol., 1999, 6, 127.
Pfeffer et al., Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction, N.Engl. J. Med., 1992, 327, 669.
Rahuel et al., Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin, Chem. Biol., 2000, 7, 493.
Remington: The Science and Practice of Pharmacy, 20thEdition, Philadelphia College of Pharmacy and Science, table of contents.
Rosenberg et al., The paradox of the renin-angiotensin system in chronic renal disease, Kidney International, 1994, 45, 403.
Vaughan et al., Angiotensin converting enzyme inhibitors and cardiovascular remodelling, Cardiovasc. Res., 1994, 28, 159.
Waeber et al., The renin-angiotensin system: role in experimental and human hypertension, Hypertension, Amsterdam, Elsevier Science Publishing Co., 1986, 489-519.
Weber, Clinical experience with the angiotensin II receptor antanoists losartan, Am. J. Hypertens., 1992, 5, 247S.

Affiliated with

Also associated with

Rating

Secondary amines as renin inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Secondary amines as renin inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Secondary amines as renin inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2715693